Additional Information
Book Details
Abstract
Now fully up to date with numerous new chapters, Netter's Obstetrics and Gynecology, 3rd Edition , by Roger P. Smith, MD, provides superbly illustrated coverage of the common conditions and problems most often encountered in ob/gyn practice. Classic Netter images are paired with concise, evidence-based descriptions of common diseases, conditions, diagnostics, treatments, and protocols. Large, clear illustrations and short, to-the-point text make this the perfect reference for everyday clinical practice as well as staff and patient education.
- More than 300 exquisite Netter images , as well as new, recent paintings by Carlos Machado provide a quick and memorable overview of each disease or condition.
- Concise text and a standardized format provide quick access to expert medical thinking.
- Entirely new sections on Embryology and Anatomy contain chapters on Sexual Differentiation, Genital Tract Development, Development of the Breast, and each area of gynecologic anatomy.
- New chapters on Chronic Pelvic Pain, BRCA1 and BRCA2 mutations, Obstetric Anesthesia and Analgesia, Subdermal Contraceptive Capsule Insertion and Removal, Trigger Point Injections, and more.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | cover | ||
| Inside Front Cover | ifc1 | ||
| FM_page i | i | ||
| FM_page ii | ii | ||
| Netter's Obstetrics and Gynecology | iii | ||
| Copyright Page | iv | ||
| Preface | v | ||
| About the Author | v | ||
| About the Artists | vi | ||
| Online Contents | vii | ||
| Table Of Contents | viii | ||
| I Anatomy and Embryology | 1 | ||
| I Embryology | 1 | ||
| 1 Sexual Differentiation | 3 | ||
| 2 Upper Genital Tract Development | 4 | ||
| 3 Lower Genital Tract Development | 5 | ||
| 4 Development of the Breast | 7 | ||
| II Anatomy | 9 | ||
| 5 External Genitalia | 11 | ||
| 6 Perineum | 12 | ||
| 7 Vagina | 13 | ||
| 8 Pelvic Viscera | 15 | ||
| 9 Cervix, Uterus, and Adnexa | 16 | ||
| 10 Ovaries | 17 | ||
| 11 Breast | 19 | ||
| II Gynecology and Women's Health | 23 | ||
| III General Health Considerations and Counseling | 23 | ||
| 12 Puberty | 25 | ||
| The Challenge | 25 | ||
| Scope of the Problem | 25 | ||
| Objectives of Management | 25 | ||
| Tactics | 25 | ||
| Relevant Pathophysiology | 25 | ||
| Strategies | 26 | ||
| Patient Education | 26 | ||
| Implementation | 26 | ||
| Special Considerations | 26 | ||
| References | 26 | ||
| Level II | 26 | ||
| Level III | 26 | ||
| 13 Health Maintenance | 26 | ||
| Important Considerations (Physiologic Changes) | 26 | ||
| Leading Causes of Death | 26 | ||
| Leading Causes of Morbidity | 26 | ||
| Screening | 26 | ||
| History | 26 | ||
| Physical | 27 | ||
| Laboratory (Only as Dictated by the Patient’s History) | 27 | ||
| Imaging | 27 | ||
| Counseling | 27 | ||
| Counseling Resources | 28 | ||
| Interventions: Immunizations | 28 | ||
| Periodic | 28 | ||
| High-Risk Groups | 28 | ||
| References | 28 | ||
| Level II | 28 | ||
| Level III | 28 | ||
| 14 Health Maintenance | 28 | ||
| Important Considerations (Physiologic Changes) | 28 | ||
| Leading Causes of Death | 28 | ||
| Leading Causes of Morbidity | 28 | ||
| Screening | 29 | ||
| History | 29 | ||
| Physical | 29 | ||
| Laboratory | 29 | ||
| Imaging | 29 | ||
| Counseling | 29 | ||
| Sexuality | 29 | ||
| Fitness | 29 | ||
| Psychosocial Evaluation | 29 | ||
| Cardiovascular Risk Factors | 29 | ||
| Health/Risk Behaviors | 30 | ||
| Injury Prevention | 30 | ||
| Counseling Resources | 30 | ||
| Interventions: Immunizations | 30 | ||
| Periodic | 30 | ||
| High-Risk Groups | 30 | ||
| References | 30 | ||
| Level II | 30 | ||
| Level III | 30 | ||
| 15 Contraception | 30 | ||
| The Challenge | 30 | ||
| Scope of the Problem | 30 | ||
| Objectives of Counseling | 30 | ||
| Tactics | 31 | ||
| Relevant Pathophysiology | 31 | ||
| Strategies | 31 | ||
| Patient Education | 31 | ||
| Implementation | 31 | ||
| Special Considerations | 31 | ||
| References | 32 | ||
| Level III | 32 | ||
| 16 Health Maintenance | 32 | ||
| Important Considerations (Physiologic Changes) | 32 | ||
| Leading Causes of Death | 32 | ||
| Leading Causes of Morbidity | 32 | ||
| Screening | 32 | ||
| History | 32 | ||
| Physical | 33 | ||
| Laboratory | 33 | ||
| Imaging | 33 | ||
| Counseling | 33 | ||
| Sexuality | 33 | ||
| Fitness | 33 | ||
| Psychosocial Evaluation | 33 | ||
| Cardiovascular Risk Factors | 33 | ||
| Health/Risk Behaviors | 33 | ||
| Counseling Resources | 33 | ||
| Interventions: Immunizations | 34 | ||
| Periodic | 34 | ||
| High-Risk Groups | 34 | ||
| References | 34 | ||
| Level I | 34 | ||
| Level II | 34 | ||
| Level III | 34 | ||
| 17 Health Maintenance | 35 | ||
| Important Considerations (Physiologic Changes) | 35 | ||
| Leading Causes of Death | 35 | ||
| Leading Causes of Morbidity | 35 | ||
| Screening | 35 | ||
| History | 35 | ||
| Physical | 35 | ||
| Laboratory | 35 | ||
| Imaging | 36 | ||
| Counseling | 36 | ||
| Sexuality | 36 | ||
| Fitness | 36 | ||
| Psychosocial Evaluation | 36 | ||
| Cardiovascular Risk Factors | 36 | ||
| Health/Risk Behaviors | 36 | ||
| Counseling Resources | 36 | ||
| Interventions: Immunizations | 36 | ||
| Periodic | 36 | ||
| High-Risk Groups | 36 | ||
| References | 37 | ||
| Level II | 37 | ||
| Level III | 37 | ||
| IV Diseases, Disorders, and Common Problems | 39 | ||
| 18 Abortion | 41 | ||
| Introduction | 41 | ||
| Etiology and Pathogenesis | 41 | ||
| Signs and Symptoms | 41 | ||
| Diagnostic Approach | 41 | ||
| Differential Diagnosis | 41 | ||
| Workup and Evaluation | 41 | ||
| Pathologic Findings | 42 | ||
| Management and Therapy | 42 | ||
| Nonpharmacologic | 42 | ||
| Drug(s) of Choice | 42 | ||
| Alternative Drugs | 42 | ||
| Follow-Up | 42 | ||
| Miscellaneous | 42 | ||
| References | 43 | ||
| Level I | 43 | ||
| Level II | 43 | ||
| Level III | 43 | ||
| 19 Abuse | 44 | ||
| Introduction | 44 | ||
| Etiology and Pathogenesis | 44 | ||
| Signs and Symptoms | 44 | ||
| Physical Abuse | 44 | ||
| Sexual Abuse | 44 | ||
| Diagnostic Approach | 44 | ||
| Differential Diagnosis | 44 | ||
| Workup and Evaluation | 44 | ||
| Pathologic Findings | 44 | ||
| Management and Therapy | 44 | ||
| Nonpharmacologic | 44 | ||
| Drug(s) of Choice | 44 | ||
| Follow-Up | 44 | ||
| Miscellaneous | 44 | ||
| References | 46 | ||
| Level II | 46 | ||
| Level III | 46 | ||
| 20 Acne | 46 | ||
| Introduction | 46 | ||
| Etiology and Pathogenesis | 46 | ||
| Signs and Symptoms | 46 | ||
| Diagnostic Approach | 46 | ||
| Differential Diagnosis | 46 | ||
| Workup and Evaluation | 47 | ||
| Pathologic Findings | 47 | ||
| Management and Therapy | 47 | ||
| Nonpharmacologic | 47 | ||
| Drug(s) of Choice | 47 | ||
| Alternative Drugs | 47 | ||
| Follow-Up | 47 | ||
| Miscellaneous | 48 | ||
| References | 48 | ||
| Level I | 48 | ||
| Level II | 48 | ||
| Level III | 48 | ||
| 21 Alzheimer Disease | 48 | ||
| Introduction | 48 | ||
| Etiology and Pathogenesis | 48 | ||
| Signs and Symptoms | 48 | ||
| Diagnostic Approach | 48 | ||
| Differential Diagnosis | 48 | ||
| Workup and Evaluation | 48 | ||
| Pathologic Findings | 49 | ||
| Management and Therapy | 49 | ||
| Nonpharmacologic | 49 | ||
| Drug(s) of Choice | 49 | ||
| Follow-Up | 50 | ||
| Miscellaneous | 50 | ||
| References | 50 | ||
| Level III | 50 | ||
| 22 Anemia | 50 | ||
| Introduction | 50 | ||
| Etiology and Pathogenesis | 50 | ||
| Signs and Symptoms | 50 | ||
| Diagnostic Approach | 50 | ||
| Differential Diagnosis | 50 | ||
| Workup and Evaluation | 50 | ||
| Pathologic Findings | 51 | ||
| Management and Therapy | 51 | ||
| Nonpharmacologic | 51 | ||
| Drug(s) of Choice | 51 | ||
| Follow-Up | 51 | ||
| Miscellaneous | 51 | ||
| References | 52 | ||
| Level III | 52 | ||
| 23 Anorectal Fistula | 52 | ||
| Introduction | 52 | ||
| Etiology and Pathogenesis | 52 | ||
| Signs and Symptoms | 52 | ||
| Diagnostic Approach | 52 | ||
| Differential Diagnosis | 52 | ||
| Workup and Evaluation | 52 | ||
| Pathologic Findings | 52 | ||
| Management and Therapy | 52 | ||
| Nonpharmacologic | 52 | ||
| Drug(s) of Choice | 52 | ||
| Follow-Up | 52 | ||
| Miscellaneous | 53 | ||
| References | 53 | ||
| Level I | 53 | ||
| Level II | 53 | ||
| Level III | 53 | ||
| 24 Anxiety | 54 | ||
| Introduction | 54 | ||
| Etiology and Pathogenesis | 54 | ||
| Signs and Symptoms (Vary With Subtype) | 54 | ||
| Diagnostic Approach | 54 | ||
| Differential Diagnosis | 54 | ||
| Workup and Evaluation | 54 | ||
| Pathologic Findings | 54 | ||
| Management and Therapy | 54 | ||
| Nonpharmacologic | 54 | ||
| Drug(s) of Choice | 54 | ||
| Alternative Drugs | 54 | ||
| Follow-Up | 54 | ||
| Miscellaneous | 55 | ||
| References | 55 | ||
| Level II | 55 | ||
| Level III | 55 | ||
| 25 Asthma | 56 | ||
| Introduction | 56 | ||
| Etiology and Pathogenesis | 56 | ||
| Signs and Symptoms | 56 | ||
| Diagnostic Approach | 56 | ||
| Differential Diagnosis | 56 | ||
| Workup and Evaluation | 56 | ||
| Pathologic Findings | 56 | ||
| Management and Therapy | 56 | ||
| Nonpharmacologic | 56 | ||
| Drug(s) of Choice | 56 | ||
| Alternative Drugs | 56 | ||
| Follow-Up | 56 | ||
| Miscellaneous | 57 | ||
| References | 57 | ||
| Level III | 57 | ||
| 26 Cholelithiasis | 58 | ||
| Introduction | 58 | ||
| Etiology and Pathogenesis | 58 | ||
| Signs and Symptoms | 58 | ||
| Diagnostic Approach | 58 | ||
| Differential Diagnosis | 58 | ||
| Workup and Evaluation | 58 | ||
| Pathologic Findings | 58 | ||
| Management and Therapy | 58 | ||
| Nonpharmacologic | 58 | ||
| Drug(s) of Choice | 59 | ||
| Follow-Up | 59 | ||
| Miscellaneous | 59 | ||
| References | 60 | ||
| Level II | 60 | ||
| Level III | 60 | ||
| 27 Chronic Pelvic Pain | 60 | ||
| Introduction | 60 | ||
| Etiology and Pathogenesis | 60 | ||
| Signs and Symptoms | 60 | ||
| Diagnostic Approach | 60 | ||
| Differential Diagnosis | 60 | ||
| Workup and Evaluation | 60 | ||
| Pathologic Findings | 61 | ||
| Management and Therapy | 61 | ||
| Nonpharmacologic | 61 | ||
| Drug(s) of Choice | 61 | ||
| Alternative Drugs | 61 | ||
| Follow-Up | 61 | ||
| Miscellaneous | 61 | ||
| References | 62 | ||
| Level I | 62 | ||
| Level II | 62 | ||
| Level III | 62 | ||
| 28 Constipation | 62 | ||
| Introduction | 62 | ||
| Etiology and Pathogenesis | 62 | ||
| Signs and Symptoms | 62 | ||
| Diagnostic Approach | 62 | ||
| Differential Diagnosis | 62 | ||
| Workup and Evaluation | 62 | ||
| Pathologic Findings | 62 | ||
| Management and Therapy | 63 | ||
| Nonpharmacologic | 63 | ||
| Drug(s) of Choice | 63 | ||
| Follow-Up | 63 | ||
| Miscellaneous | 63 | ||
| References | 64 | ||
| Level I | 64 | ||
| Level III | 64 | ||
| 29 Crohn Disease | 64 | ||
| Introduction | 64 | ||
| Etiology and Pathogenesis | 64 | ||
| Signs and Symptoms | 64 | ||
| Diagnostic Approach | 64 | ||
| Differential Diagnosis | 64 | ||
| Workup and Evaluation | 64 | ||
| Pathologic Findings | 64 | ||
| Management and Therapy | 64 | ||
| Nonpharmacologic | 64 | ||
| Drug(s) of Choice | 65 | ||
| Follow-Up | 65 | ||
| Miscellaneous | 65 | ||
| References | 65 | ||
| Level II | 65 | ||
| Level III | 65 | ||
| 30 Depression (Unipolar) | 66 | ||
| Introduction | 66 | ||
| Etiology and Pathogenesis | 66 | ||
| Signs and Symptoms | 66 | ||
| Diagnostic Approach | 66 | ||
| Differential Diagnosis | 66 | ||
| Workup and Evaluation | 66 | ||
| Pathologic Findings | 66 | ||
| Management and Therapy | 66 | ||
| Nonpharmacologic | 66 | ||
| Drug(s) of Choice | 66 | ||
| Alternative Drugs | 66 | ||
| Follow-Up | 67 | ||
| Miscellaneous | 67 | ||
| References | 67 | ||
| Level II | 67 | ||
| Level III | 67 | ||
| 31 Diverticular Disease | 68 | ||
| Introduction | 68 | ||
| Etiology and Pathogenesis | 68 | ||
| Signs and Symptoms | 68 | ||
| Diagnostic Approach | 68 | ||
| Differential Diagnosis | 68 | ||
| Workup and Evaluation | 68 | ||
| Pathologic Findings | 68 | ||
| Management and Therapy | 68 | ||
| Nonpharmacologic | 68 | ||
| Drug(s) of Choice | 68 | ||
| Alternative Drugs | 68 | ||
| Follow-Up | 68 | ||
| Miscellaneous | 69 | ||
| References | 69 | ||
| Level II | 69 | ||
| Level III | 69 | ||
| 32 Domestic Violence | 69 | ||
| Introduction | 69 | ||
| Etiology and Pathogenesis | 70 | ||
| Signs and Symptoms | 70 | ||
| Diagnostic Approach | 70 | ||
| Differential Diagnosis | 70 | ||
| Workup and Evaluation | 70 | ||
| Pathologic Findings | 70 | ||
| Management and Therapy | 70 | ||
| Nonpharmacologic | 70 | ||
| Drug(s) of Choice | 70 | ||
| Follow-Up | 70 | ||
| Miscellaneous | 71 | ||
| References | 71 | ||
| Level I | 71 | ||
| Level II | 71 | ||
| Level III | 71 | ||
| 33 Dysmenorrhea | 71 | ||
| Introduction | 71 | ||
| Etiology and Pathogenesis | 71 | ||
| Signs and Symptoms | 72 | ||
| Diagnostic Approach | 72 | ||
| Differential Diagnosis | 72 | ||
| Workup and Evaluation | 72 | ||
| Pathologic Findings | 72 | ||
| Management and Therapy | 72 | ||
| Nonpharmacologic | 72 | ||
| Drug(s) of Choice | 73 | ||
| Alternative Drugs | 73 | ||
| Follow-Up | 73 | ||
| Miscellaneous | 73 | ||
| References | 73 | ||
| Level I | 73 | ||
| Level III | 73 | ||
| 34 Dyspareunia | 73 | ||
| Introduction | 73 | ||
| Etiology and Pathogenesis | 73 | ||
| Causes | 73 | ||
| Signs and Symptoms | 74 | ||
| Diagnostic Approach | 74 | ||
| Differential Diagnosis | 74 | ||
| Workup and Evaluation | 74 | ||
| Pathologic Findings | 74 | ||
| Management and Therapy | 74 | ||
| Nonpharmacologic | 74 | ||
| Drug(s) of Choice | 74 | ||
| Alternative Therapies | 74 | ||
| Follow-Up | 74 | ||
| Miscellaneous | 75 | ||
| References | 75 | ||
| Level III | 75 | ||
| 35 Dysuria | 75 | ||
| Introduction | 75 | ||
| Etiology and Pathogenesis | 75 | ||
| Signs and Symptoms | 75 | ||
| Diagnostic Approach | 75 | ||
| Differential Diagnosis | 75 | ||
| Workup and Evaluation | 75 | ||
| Pathologic Findings | 76 | ||
| Management and Therapy | 76 | ||
| Nonpharmacologic | 76 | ||
| Drug(s) of Choice (Nonpregnant Patients) | 76 | ||
| Alternative Drugs (Pregnant Patients) | 77 | ||
| Follow-Up | 77 | ||
| Miscellaneous | 77 | ||
| References | 77 | ||
| Level III | 77 | ||
| 36 Eating Disorders | 77 | ||
| Introduction | 77 | ||
| Etiology and Pathogenesis | 77 | ||
| Signs and Symptoms | 77 | ||
| Diagnostic Approach | 78 | ||
| Differential Diagnosis | 78 | ||
| Workup and Evaluation | 78 | ||
| Pathologic Findings | 78 | ||
| Management and Therapy | 78 | ||
| Nonpharmacologic | 78 | ||
| Drug(s) of Choice | 79 | ||
| Alternative Drugs | 79 | ||
| Follow-Up | 79 | ||
| Miscellaneous | 79 | ||
| References | 79 | ||
| Level I | 79 | ||
| Level II | 79 | ||
| Level III | 79 | ||
| 37 Fibromyalgia | 79 | ||
| Introduction | 79 | ||
| Etiology and Pathogenesis | 80 | ||
| Signs and Symptoms | 80 | ||
| Diagnostic Approach | 80 | ||
| Differential Diagnosis | 80 | ||
| Workup and Evaluation | 81 | ||
| Pathologic Findings | 81 | ||
| Management and Therapy | 81 | ||
| Nonpharmacologic | 81 | ||
| Drug(s) of Choice | 81 | ||
| Follow-Up | 81 | ||
| Miscellaneous | 81 | ||
| References | 81 | ||
| Level II | 81 | ||
| Level III | 81 | ||
| 38 Gallbladder Disease | 82 | ||
| Introduction | 82 | ||
| Etiology and Pathogenesis | 82 | ||
| Signs and Symptoms | 82 | ||
| Diagnostic Approach | 82 | ||
| Differential Diagnosis | 82 | ||
| Workup and Evaluation | 82 | ||
| Pathologic Findings | 82 | ||
| Management and Therapy | 82 | ||
| Nonpharmacologic | 82 | ||
| Drug(s) of Choice | 82 | ||
| Follow-Up | 83 | ||
| Miscellaneous | 83 | ||
| References | 83 | ||
| Level II | 83 | ||
| Level III | 83 | ||
| 39 Gastritis | 84 | ||
| Introduction | 84 | ||
| Etiology and Pathogenesis | 84 | ||
| Signs and Symptoms | 84 | ||
| Diagnostic Approach | 84 | ||
| Differential Diagnosis | 84 | ||
| Workup and Evaluation | 84 | ||
| Pathologic Findings | 84 | ||
| Management and Therapy | 84 | ||
| Nonpharmacologic | 84 | ||
| Drug(s) of Choice | 84 | ||
| Alternative Drugs | 84 | ||
| Follow-Up | 84 | ||
| Miscellaneous | 84 | ||
| References | 85 | ||
| Level II | 85 | ||
| Level III | 85 | ||
| 40 Gastroesophageal Reflux | 85 | ||
| Introduction | 85 | ||
| Etiology and Pathogenesis | 85 | ||
| Signs and Symptoms | 86 | ||
| Diagnostic Approach | 86 | ||
| Differential Diagnosis | 86 | ||
| Workup and Evaluation | 86 | ||
| Pathologic Findings | 86 | ||
| Management and Therapy | 86 | ||
| Nonpharmacologic | 86 | ||
| Drug(s) of Choice | 86 | ||
| Alternative Drugs | 87 | ||
| Follow-Up | 87 | ||
| Miscellaneous | 87 | ||
| References | 87 | ||
| Level II | 87 | ||
| Level III | 87 | ||
| 41 Hair Loss | 87 | ||
| Introduction | 87 | ||
| Etiology and Pathogenesis | 87 | ||
| Signs and Symptoms | 88 | ||
| Diagnostic Approach | 88 | ||
| Differential Diagnosis | 88 | ||
| Workup and Evaluation | 88 | ||
| Pathologic Findings | 88 | ||
| Management and Therapy | 88 | ||
| Nonpharmacologic | 88 | ||
| Drug(s) of Choice | 89 | ||
| Alternative Drugs | 89 | ||
| Follow-Up | 89 | ||
| Miscellaneous | 89 | ||
| References | 89 | ||
| Level II | 89 | ||
| Level III | 89 | ||
| 42 Headache | 89 | ||
| Introduction | 89 | ||
| Etiology and Pathogenesis | 89 | ||
| Signs and Symptoms | 90 | ||
| Tension Headache | 90 | ||
| Cluster Headache | 90 | ||
| Diagnostic Approach | 90 | ||
| Differential Diagnosis | 90 | ||
| Workup and Evaluation | 90 | ||
| Pathologic Findings | 90 | ||
| Management and Therapy | 90 | ||
| Nonpharmacologic | 90 | ||
| Drug(s) of Choice | 91 | ||
| Alternative Drugs | 91 | ||
| Follow-Up | 91 | ||
| Miscellaneous | 91 | ||
| References | 91 | ||
| Level II | 91 | ||
| Level III | 91 | ||
| 43 Headache | 92 | ||
| Introduction | 92 | ||
| Etiology and Pathogenesis | 92 | ||
| Signs and Symptoms | 92 | ||
| Diagnostic Approach | 92 | ||
| Differential Diagnosis | 92 | ||
| Workup and Evaluation | 92 | ||
| Pathologic Findings | 92 | ||
| Management and Therapy | 92 | ||
| Nonpharmacologic | 92 | ||
| Drug(s) of Choice | 92 | ||
| Alternative Drugs | 92 | ||
| Follow-Up | 93 | ||
| Miscellaneous | 93 | ||
| References | 94 | ||
| Level I | 94 | ||
| Level II | 94 | ||
| Level III | 94 | ||
| 44 Hematuria | 94 | ||
| Introduction | 94 | ||
| Etiology and Pathogenesis | 94 | ||
| Signs and Symptoms | 94 | ||
| Diagnostic Approach | 94 | ||
| Differential Diagnosis | 94 | ||
| Workup and Evaluation | 94 | ||
| Pathologic Findings | 94 | ||
| Management and Therapy | 94 | ||
| Nonpharmacologic | 94 | ||
| Drug(s) of Choice | 95 | ||
| Follow-Up | 95 | ||
| Miscellaneous | 95 | ||
| References | 95 | ||
| Level III | 95 | ||
| 45 Hemorrhoids | 96 | ||
| Introduction | 96 | ||
| Etiology and Pathogenesis | 96 | ||
| Signs and Symptoms | 96 | ||
| Diagnostic Approach | 96 | ||
| Differential Diagnosis | 96 | ||
| Workup and Evaluation | 96 | ||
| Pathologic Findings | 96 | ||
| Management and Therapy | 96 | ||
| Nonpharmacologic | 96 | ||
| Drug(s) of Choice | 96 | ||
| Alternative Drugs | 96 | ||
| Follow-Up | 96 | ||
| Miscellaneous | 96 | ||
| References | 97 | ||
| Level II | 97 | ||
| Level III | 97 | ||
| 46 Hyperthyroidism | 97 | ||
| Introduction | 97 | ||
| Etiology and Pathogenesis | 97 | ||
| Signs and Symptoms | 97 | ||
| Diagnostic Approach | 98 | ||
| Differential Diagnosis | 98 | ||
| Workup and Evaluation | 98 | ||
| Pathologic Findings | 98 | ||
| Management and Therapy | 98 | ||
| Nonpharmacologic | 98 | ||
| Drug(s) of Choice | 98 | ||
| Alternative Drugs | 99 | ||
| Follow-Up | 99 | ||
| Miscellaneous | 99 | ||
| References | 99 | ||
| Level II | 99 | ||
| Level III | 99 | ||
| 47 Hypothyroidism | 99 | ||
| Introduction | 99 | ||
| Etiology and Pathogenesis | 99 | ||
| Signs and Symptoms | 99 | ||
| Diagnostic Approach | 100 | ||
| Differential Diagnosis | 100 | ||
| Workup and Evaluation | 100 | ||
| Pathologic Findings | 100 | ||
| Management and Therapy | 100 | ||
| Nonpharmacologic | 100 | ||
| Drug(s) of Choice | 100 | ||
| Follow-Up | 101 | ||
| Miscellaneous | 101 | ||
| References | 101 | ||
| Level II | 101 | ||
| Level III | 101 | ||
| 48 Infertility | 101 | ||
| The Challenge | 101 | ||
| Tactics | 102 | ||
| Implementation | 103 | ||
| References | 103 | ||
| Level II | 103 | ||
| Level III | 103 | ||
| 49 Irritable Bowel Syndrome | 103 | ||
| Introduction | 103 | ||
| Etiology and Pathogenesis | 103 | ||
| Signs and Symptoms | 104 | ||
| Diagnostic Approach | 104 | ||
| Differential Diagnosis | 104 | ||
| Workup and Evaluation | 104 | ||
| Pathologic Findings | 104 | ||
| Management and Therapy | 104 | ||
| Nonpharmacologic | 104 | ||
| Drug(s) of Choice | 105 | ||
| Alternative Drugs | 105 | ||
| Follow-Up | 105 | ||
| Miscellaneous | 105 | ||
| References | 105 | ||
| Level I | 105 | ||
| Level II | 105 | ||
| Level III | 105 | ||
| 50 Low Back Pain | 105 | ||
| Introduction | 105 | ||
| Etiology and Pathogenesis | 105 | ||
| Signs and Symptoms | 106 | ||
| Diagnostic Approach | 106 | ||
| Differential Diagnosis | 106 | ||
| Workup and Evaluation | 107 | ||
| Pathologic Findings | 107 | ||
| Management and Therapy | 107 | ||
| Nonpharmacologic | 107 | ||
| Drug(s) of Choice | 107 | ||
| Follow-Up | 107 | ||
| Miscellaneous | 107 | ||
| References | 107 | ||
| Level I | 107 | ||
| Level II | 107 | ||
| Level III | 108 | ||
| 51 Melanoma | 108 | ||
| Introduction | 108 | ||
| Etiology and Pathogenesis | 108 | ||
| Signs and Symptoms | 108 | ||
| Diagnostic Approach | 108 | ||
| Differential Diagnosis | 108 | ||
| Workup and Evaluation | 108 | ||
| Pathologic Findings | 108 | ||
| Management and Therapy | 108 | ||
| Nonpharmacologic | 108 | ||
| Drug(s) of Choice | 108 | ||
| Follow-Up | 109 | ||
| Miscellaneous | 109 | ||
| References | 109 | ||
| Level I | 109 | ||
| Level II | 109 | ||
| Level III | 109 | ||
| 52 Myofascial Syndromes | 110 | ||
| Introduction | 110 | ||
| Etiology and Pathogenesis | 110 | ||
| Signs and Symptoms | 110 | ||
| Diagnostic Approach | 110 | ||
| Differential Diagnosis | 110 | ||
| Workup and Evaluation | 110 | ||
| Pathologic Findings | 110 | ||
| Management and Therapy | 110 | ||
| Nonpharmacologic | 110 | ||
| Drug(s) of Choice | 110 | ||
| Alternative Drugs | 111 | ||
| Follow-Up | 111 | ||
| Miscellaneous | 111 | ||
| References | 111 | ||
| Level I | 111 | ||
| Level III | 111 | ||
| 53 Obesity | 112 | ||
| Introduction | 112 | ||
| Etiology and Pathogenesis | 112 | ||
| Signs and Symptoms | 112 | ||
| Diagnostic Approach | 112 | ||
| Differential Diagnosis | 112 | ||
| Workup and Evaluation | 112 | ||
| Pathologic Findings | 112 | ||
| Management and Therapy | 112 | ||
| Nonpharmacologic | 112 | ||
| Drug(s) of Choice | 112 | ||
| Alternative Drugs | 113 | ||
| Follow-Up | 113 | ||
| Miscellaneous | 113 | ||
| References | 113 | ||
| Level I | 113 | ||
| Level II | 114 | ||
| Level III | 114 | ||
| 54 Osteoporosis | 114 | ||
| Introduction | 114 | ||
| Etiology and Pathogenesis | 114 | ||
| Signs and Symptoms | 114 | ||
| Diagnostic Approach | 115 | ||
| Differential Diagnosis | 115 | ||
| Workup and Evaluation | 115 | ||
| Pathologic Findings | 115 | ||
| Management and Therapy | 115 | ||
| Nonpharmacologic | 115 | ||
| Drug(s) of Choice | 116 | ||
| Alternative Drugs | 116 | ||
| Follow-Up | 116 | ||
| Miscellaneous | 117 | ||
| References | 117 | ||
| Level I | 117 | ||
| Level II | 117 | ||
| Level III | 117 | ||
| 55 Pessary Therapy | 117 | ||
| The Challenge | 117 | ||
| Tactics | 117 | ||
| Implementation | 118 | ||
| References | 119 | ||
| Level I | 119 | ||
| Level II | 119 | ||
| Level III | 119 | ||
| 56 Postcoital Bleeding | 119 | ||
| Introduction | 119 | ||
| Etiology and Pathogenesis | 119 | ||
| Signs and Symptoms | 119 | ||
| Diagnostic Approach | 119 | ||
| Differential Diagnosis | 119 | ||
| Workup and Evaluation | 119 | ||
| Pathologic Findings | 119 | ||
| Management and Therapy | 119 | ||
| Nonpharmacologic | 119 | ||
| Drug(s) of Choice | 120 | ||
| Follow-Up | 120 | ||
| Miscellaneous | 120 | ||
| References | 120 | ||
| Level I | 120 | ||
| Level II | 120 | ||
| 57 Premenstrual Syndrome | 121 | ||
| Introduction | 121 | ||
| Etiology and Pathogenesis | 121 | ||
| Signs and Symptoms | 121 | ||
| Diagnostic Approach | 121 | ||
| Differential Diagnosis | 121 | ||
| Workup and Evaluation | 121 | ||
| Pathologic Findings | 121 | ||
| Management and Therapy | 121 | ||
| Nonpharmacologic | 121 | ||
| Drug(s) of Choice | 121 | ||
| Follow-Up | 121 | ||
| Miscellaneous | 122 | ||
| References | 122 | ||
| Level I | 122 | ||
| Level II | 122 | ||
| Level III | 123 | ||
| 58 Pruritus Ani | 123 | ||
| Introduction | 123 | ||
| Etiology and Pathogenesis | 123 | ||
| Signs and Symptoms | 123 | ||
| Diagnostic Approach | 123 | ||
| Differential Diagnosis | 123 | ||
| Workup and Evaluation | 123 | ||
| Pathologic Findings | 123 | ||
| Management and Therapy | 123 | ||
| Nonpharmacologic | 123 | ||
| Drug(s) of Choice | 124 | ||
| Follow-Up | 124 | ||
| Miscellaneous | 124 | ||
| References | 124 | ||
| Level I | 124 | ||
| Level II | 124 | ||
| Level III | 124 | ||
| 59 Rape and Rape Trauma Syndrome | 124 | ||
| Introduction | 124 | ||
| Etiology and Pathogenesis | 125 | ||
| Signs and Symptoms | 125 | ||
| Diagnostic Approach | 126 | ||
| Differential Diagnosis | 126 | ||
| Workup and Evaluation | 126 | ||
| Pathologic Findings | 126 | ||
| Management and Therapy | 126 | ||
| Nonpharmacologic | 126 | ||
| Drug(s) of Choice | 126 | ||
| Alternative Drugs | 126 | ||
| Follow-Up | 126 | ||
| Miscellaneous | 127 | ||
| References | 127 | ||
| Level II | 127 | ||
| Level III | 127 | ||
| 60 Sexual Dysfunction | 127 | ||
| Introduction | 127 | ||
| Signs and Symptoms | 127 | ||
| Diagnostic Approach | 128 | ||
| Differential Diagnosis | 128 | ||
| Workup and Evaluation | 128 | ||
| Pathologic Findings | 128 | ||
| Management and Therapy | 128 | ||
| Drug(s) of Choice | 128 | ||
| Alternative Therapies | 129 | ||
| References | 129 | ||
| Level I | 129 | ||
| Level II | 129 | ||
| Level III | 129 | ||
| 61 Sexually Transmitted Infections | 129 | ||
| Introduction | 129 | ||
| Etiology and Pathogenesis | 129 | ||
| Signs and Symptoms | 129 | ||
| Diagnostic Approach | 129 | ||
| Differential Diagnosis | 129 | ||
| Workup and Evaluation | 130 | ||
| Pathologic Findings | 130 | ||
| Management and Therapy | 130 | ||
| Nonpharmacologic | 130 | ||
| Drug(s) of Choice | 130 | ||
| Alternative Drugs | 130 | ||
| Follow-Up | 130 | ||
| Miscellaneous | 130 | ||
| References | 131 | ||
| Level I | 131 | ||
| Level II | 131 | ||
| Level III | 131 | ||
| 62 Sexually Transmitted Infections | 131 | ||
| Introduction | 131 | ||
| Etiology and Pathogenesis | 131 | ||
| Signs and Symptoms | 131 | ||
| Diagnostic Approach | 131 | ||
| Differential Diagnosis | 131 | ||
| Workup and Evaluation | 131 | ||
| Pathologic Findings | 132 | ||
| Management and Therapy | 132 | ||
| Nonpharmacologic | 132 | ||
| Drug(s) of Choice | 132 | ||
| Alternative Drugs | 132 | ||
| Follow-Up | 132 | ||
| Miscellaneous | 132 | ||
| References | 133 | ||
| Level II | 133 | ||
| Level III | 133 | ||
| 63 Sexually Transmitted Infections | 133 | ||
| Introduction | 133 | ||
| Etiology and Pathogenesis | 133 | ||
| Signs and Symptoms | 133 | ||
| Diagnostic Approach | 133 | ||
| Differential Diagnosis | 133 | ||
| Workup and Evaluation | 134 | ||
| Pathologic Findings | 134 | ||
| Management and Therapy | 134 | ||
| Nonpharmacologic | 134 | ||
| Drug(s) of Choice | 134 | ||
| Alternative Drugs | 134 | ||
| Follow-Up | 134 | ||
| Miscellaneous | 135 | ||
| References | 135 | ||
| Level I | 135 | ||
| Level II | 135 | ||
| Level III | 135 | ||
| 64 Sexually Transmitted Infections | 135 | ||
| Introduction | 135 | ||
| Etiology and Pathogenesis | 135 | ||
| Signs and Symptoms | 135 | ||
| Diagnostic Approach | 135 | ||
| Differential Diagnosis | 135 | ||
| Workup and Evaluation | 136 | ||
| Pathologic Findings | 136 | ||
| Management and Therapy | 136 | ||
| Nonpharmacologic | 136 | ||
| Drug(s) of Choice | 136 | ||
| Alternative Drugs | 136 | ||
| Follow-Up | 136 | ||
| Miscellaneous | 137 | ||
| References | 137 | ||
| Level II | 137 | ||
| Level III | 137 | ||
| 65 Sexually Transmitted Infections | 137 | ||
| Introduction | 137 | ||
| Etiology and Pathogenesis | 137 | ||
| Signs and Symptoms | 137 | ||
| Diagnostic Approach | 137 | ||
| Differential Diagnosis | 137 | ||
| Workup and Evaluation | 138 | ||
| Pathologic Findings | 138 | ||
| Management and Therapy | 138 | ||
| Nonpharmacologic | 138 | ||
| Drug(s) of Choice | 138 | ||
| Alternative Drugs | 138 | ||
| Follow-Up | 138 | ||
| Miscellaneous | 138 | ||
| References | 139 | ||
| Level III | 139 | ||
| 66 Sexually Transmitted Infections | 139 | ||
| Introduction | 139 | ||
| Etiology and Pathogenesis | 139 | ||
| Signs and Symptoms | 139 | ||
| Diagnostic Approach | 139 | ||
| Differential Diagnosis | 139 | ||
| Workup and Evaluation | 139 | ||
| Pathologic Findings | 139 | ||
| Management and Therapy | 140 | ||
| Nonpharmacologic | 140 | ||
| Drug(s) of Choice | 140 | ||
| Alternative Drugs | 140 | ||
| Follow-Up | 140 | ||
| Miscellaneous | 141 | ||
| References | 141 | ||
| Level I | 141 | ||
| Level II | 141 | ||
| Level III | 141 | ||
| 67 Sexually Transmitted Infections | 141 | ||
| Introduction | 141 | ||
| Etiology and Pathogenesis | 142 | ||
| Signs and Symptoms | 142 | ||
| Diagnostic Approach | 143 | ||
| Differential Diagnosis | 143 | ||
| Workup and Evaluation | 143 | ||
| Pathologic Findings | 143 | ||
| Management and Therapy | 143 | ||
| Nonpharmacologic | 143 | ||
| Drug(s) of Choice | 143 | ||
| Follow-Up | 143 | ||
| Miscellaneous | 143 | ||
| References | 143 | ||
| Level I | 143 | ||
| Level II | 143 | ||
| Level III | 144 | ||
| 68 Sexually Transmitted Infections | 144 | ||
| Introduction | 144 | ||
| Etiology and Pathogenesis | 144 | ||
| Signs and Symptoms | 144 | ||
| Diagnostic Approach | 145 | ||
| Differential Diagnosis | 145 | ||
| Workup and Evaluation | 145 | ||
| Pathologic Findings | 145 | ||
| Management and Therapy | 145 | ||
| Nonpharmacologic | 145 | ||
| Drug(s) of Choice | 145 | ||
| Follow-Up | 145 | ||
| Miscellaneous | 145 | ||
| References | 146 | ||
| Level I | 146 | ||
| Level II | 146 | ||
| Level III | 146 | ||
| 69 Sexually Transmitted Infections | 147 | ||
| Introduction | 147 | ||
| Etiology and Pathogenesis | 147 | ||
| Signs and Symptoms | 147 | ||
| Diagnostic Approach | 147 | ||
| Differential Diagnosis | 147 | ||
| Workup and Evaluation | 147 | ||
| Pathologic Findings | 147 | ||
| Management and Therapy | 147 | ||
| Nonpharmacologic | 147 | ||
| Drug(s) of Choice | 147 | ||
| Alternative Drugs | 148 | ||
| Follow-Up | 148 | ||
| Miscellaneous | 148 | ||
| References | 148 | ||
| Level II | 148 | ||
| Level III | 148 | ||
| 70 Sexually Transmitted Infections | 149 | ||
| Introduction | 149 | ||
| Etiology and Pathogenesis | 149 | ||
| Signs and Symptoms | 149 | ||
| Diagnostic Approach | 149 | ||
| Differential Diagnosis | 149 | ||
| Workup and Evaluation | 149 | ||
| Pathologic Findings | 150 | ||
| Management and Therapy | 150 | ||
| Nonpharmacologic | 150 | ||
| Drug(s) of Choice | 150 | ||
| Follow-Up | 150 | ||
| Miscellaneous | 150 | ||
| References | 150 | ||
| Level I | 150 | ||
| Level II | 150 | ||
| Level III | 150 | ||
| 71 Sexually Transmitted Infections | 150 | ||
| Introduction | 150 | ||
| Etiology and Pathogenesis | 150 | ||
| Signs and Symptoms | 151 | ||
| Diagnostic Approach | 151 | ||
| Differential Diagnosis | 151 | ||
| Workup and Evaluation | 151 | ||
| Pathologic Findings | 151 | ||
| Management and Therapy | 151 | ||
| Nonpharmacologic | 151 | ||
| Drug(s) of Choice | 151 | ||
| Alternative Drugs | 152 | ||
| Follow-Up | 152 | ||
| Miscellaneous | 152 | ||
| References | 152 | ||
| Level II | 152 | ||
| Level III | 152 | ||
| 72 Sexually Transmitted Infections | 152 | ||
| Introduction | 152 | ||
| Etiology and Pathogenesis | 152 | ||
| Signs and Symptoms (Based on Stage) | 152 | ||
| Diagnostic Approach | 152 | ||
| Differential Diagnosis | 152 | ||
| Workup and Evaluation | 154 | ||
| Pathologic Findings | 154 | ||
| Management and Therapy | 154 | ||
| Nonpharmacologic | 154 | ||
| Drug(s) of Choice | 154 | ||
| Alternative Drugs | 154 | ||
| Follow-Up | 154 | ||
| Miscellaneous | 154 | ||
| References | 154 | ||
| Level I | 154 | ||
| Level II | 154 | ||
| Level III | 155 | ||
| 73 Sexually Transmitted Infections | 155 | ||
| Introduction | 155 | ||
| Etiology and Pathogenesis | 155 | ||
| Signs and Symptoms | 155 | ||
| Diagnostic Approach | 155 | ||
| Differential Diagnosis | 155 | ||
| Workup and Evaluation | 155 | ||
| Pathologic Findings | 155 | ||
| Management and Therapy | 155 | ||
| Nonpharmacologic | 155 | ||
| Drug(s) of Choice | 155 | ||
| Alternative Drugs | 156 | ||
| Follow-Up | 156 | ||
| Miscellaneous | 156 | ||
| References | 156 | ||
| Level II | 156 | ||
| Level III | 156 | ||
| 74 Thrombophlebitis | 157 | ||
| Introduction | 157 | ||
| Etiology and Pathogenesis | 157 | ||
| Signs and Symptoms | 157 | ||
| Diagnostic Approach | 157 | ||
| Differential Diagnosis | 157 | ||
| Workup and Evaluation | 157 | ||
| Pathologic Findings | 157 | ||
| Management and Therapy | 157 | ||
| Nonpharmacologic | 157 | ||
| Drug(s) of Choice | 157 | ||
| Alternative Drugs | 158 | ||
| Follow-Up | 158 | ||
| Miscellaneous | 159 | ||
| References | 159 | ||
| Level I | 159 | ||
| Level II | 159 | ||
| Level III | 159 | ||
| 75 Toxic Shock Syndrome | 159 | ||
| Introduction | 159 | ||
| Etiology and Pathogenesis | 159 | ||
| Signs and Symptoms | 159 | ||
| Diagnostic Approach | 160 | ||
| Differential Diagnosis | 160 | ||
| Workup and Evaluation | 160 | ||
| Pathologic Findings | 161 | ||
| Management and Therapy | 161 | ||
| Nonpharmacologic | 161 | ||
| Drug(s) of Choice | 161 | ||
| Alternative Drugs | 161 | ||
| Follow-Up | 161 | ||
| Miscellaneous | 161 | ||
| References | 161 | ||
| Level II | 161 | ||
| Level III | 161 | ||
| 76 Ulcerative Colitis | 162 | ||
| Introduction | 162 | ||
| Etiology and Pathogenesis | 162 | ||
| Signs and Symptoms | 162 | ||
| Diagnostic Approach | 162 | ||
| Differential Diagnosis | 162 | ||
| Workup and Evaluation | 162 | ||
| Pathologic Findings | 162 | ||
| Management and Therapy | 162 | ||
| Nonpharmacologic | 162 | ||
| Drug(s) of Choice | 162 | ||
| Alternative Drugs | 162 | ||
| Follow-Up | 162 | ||
| Miscellaneous | 163 | ||
| References | 163 | ||
| Level I | 163 | ||
| Level II | 163 | ||
| Level III | 164 | ||
| 77 Urinary Incontinence | 164 | ||
| Introduction | 164 | ||
| Etiology and Pathogenesis | 164 | ||
| Signs and Symptoms | 164 | ||
| III Obstetrics | 411 | ||
| XII Obstetrics: General Considerations | 411 | ||
| 197 Preconceptional Care and Counseling | 413 | ||
| The Challenge | 413 | ||
| Tactics | 413 | ||
| Implementation | 414 | ||
| References | 414 | ||
| Level II | 414 | ||
| Level III | 414 | ||
| 198 Routine Prenatal Care | 415 | ||
| The Challenge | 415 | ||
| Tactics | 415 | ||
| Implementation | 416 | ||
| References | 416 | ||
| Level III | 416 | ||
| 199 Routine Prenatal Care | 416 | ||
| The Challenge | 416 | ||
| Tactics | 417 | ||
| Implementation | 418 | ||
| References | 418 | ||
| Level III | 418 | ||
| 200 Routine Prenatal Care | 418 | ||
| The Challenge | 418 | ||
| Tactics | 418 | ||
| IV Procedures | 515 | ||
| XIV Procedures | 515 | ||
| 249 Amniocentesis | 517 | ||
| Description | 517 | ||
| Indications | 517 | ||
| Contraindications | 517 | ||
| Required Equipment | 517 | ||
| Technique | 517 | ||
| Complications | 517 | ||
| Follow-Up | 518 | ||
| CPT Code(s) | 518 | ||
| References | 518 | ||
| Level I | 518 | ||
| Level II | 518 | ||
| Level III | 518 | ||
| 250 Aspiration of Breast Cyst | 518 | ||
| Description | 518 | ||
| Indications | 518 | ||
| Contraindications | 518 | ||
| Required Equipment | 518 | ||
| Technique | 518 | ||
| Complications | 519 | ||
| Follow-Up | 519 | ||
| CPT Code(s) | 519 | ||
| References | 519 | ||
| Level II | 519 | ||
| Level III | 519 | ||
| 251 Bartholin Gland Cyst/Abscess Drainage | 520 | ||
| Description | 520 | ||
| Indications | 520 | ||
| Contraindications | 520 | ||
| Required Equipment | 520 | ||
| Technique | 520 | ||
| Index | 581 | ||
| A | 581 | ||
| B | 582 | ||
| C | 583 | ||
| D | 586 | ||
| E | 587 | ||
| F | 588 | ||
| G | 588 | ||
| H | 589 | ||
| I | 590 | ||
| J | 591 | ||
| K | 591 | ||
| L | 591 | ||
| M | 592 | ||
| N | 593 | ||
| O | 594 | ||
| P | 594 | ||
| Q | 596 | ||
| R | 596 | ||
| S | 597 | ||
| T | 598 | ||
| U | 599 | ||
| V | 600 | ||
| W | 600 | ||
| X | 601 | ||
| Y | 601 | ||
| Z | 601 | ||
| Inside Back Cover | ibc1 |